Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin–timolol fixed combinations in primary open-angle glaucoma

References

• Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844-51
   PubMed Web of Science ®Google Scholar
• Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996;80:389-93
   PubMed Web of Science ®Google Scholar
• Cedrone C, Mancino R, Cerulli A, et al. Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects. Prog Brain Res 2008;173:3-14
   PubMed Web of Science ®Google Scholar
• Forsman E, Kivela T, Vesti E. Lifetime visual disability in open-angle glaucoma and ocular hypertension. J Glaucoma 2007;16:313-19
   PubMed Web of Science ®Google Scholar
• Wilson MR, Coleman AL, Yu F, et al. Functional status and well-being in patients with glaucoma as measured by the Medical Outcomes Study Short Form-36 questionnaire. Ophthalmology 1998;105:2112-16
   PubMed Web of Science ®Google Scholar
• Wu SY, Hennis A, Nemesure B, et al. Impact of glaucoma, lens opacities, and cataract surgery on visual functioning and related quality of life: the Barbados Eye Studies. Invest Ophthalmol Vis Sci 2008;49:1333-8
   PubMed Web of Science ®Google Scholar
• McKean-Cowdin R, Wang Y, Wu J, et al. Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study. Ophthalmology 2008;115:941-8
   PubMed Web of Science ®Google Scholar
• European Glaucoma Society. Terminology and Guidelines for Glaucoma, 3rd edn. Savona, Italy: Editrice Dogma, 2008
   Google Scholar
• Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79
   PubMed Web of Science ®Google Scholar
• Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 1998;126:487-97
   PubMed Web of Science ®Google Scholar
• Advanced Glaucoma Intervention Study. The Advanced Glaucoma Intervention Study (AGIS): the relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000;130:429-40
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
   PubMed Web of Science ®Google Scholar
• Chauhan BC, Garway-Heath DF, Goni FJ, et al. Practical recommendations for measuring rates of visual field change in glaucoma. Br J Ophthalmol 2008;92:569-73
   PubMed Web of Science ®Google Scholar
• Nasser QJ, Stewart WC. Glaucoma treatment and diagnostic trends. Rev Ophthalmol 2006;13:Article 908
   Google Scholar
• Stewart WC, Stewart JA, Nelson LA, et al. Physician attitudes regarding prostaglandin treatment for glaucoma in the United States and Europe. Eur J Ophthalmol 2008;18:199-204
   PubMed Web of Science ®Google Scholar
• Stewart WC, Jenkins JN, Stewart JA. Survey assesses prostaglandin use. Rev Ophthalmol 2005;12:Article 844
   Google Scholar
• Stewart WC, Konstas AG, Pfeiffer N. Patient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatment. J Ocul Pharmacol Ther 2004;20:461-9
   PubMed Web of Science ®Google Scholar
• Olthoff CM, Schouten JS, van de Borne BW, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology 2005;112:953-61
   PubMed Web of Science ®Google Scholar
• Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically. The Travatan Dosing Aid study. Ophthalmology 2009;116:191-9
   PubMed Web of Science ®Google Scholar
• Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995;26:233-6
   PubMedGoogle Scholar
• Taylor SA, Galbraith SM, Mills RP. Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. J Ocul Pharmacol Ther 2002;18:401-9
   PubMed Web of Science ®Google Scholar
• Djafari F, Lesk MR, Harasymowycz PJ, et al. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma 2009;18:238-43
   PubMed Web of Science ®Google Scholar
• Chauhan BC, Mikelberg FS, Balaszi AG, et al. Canadian Glaucoma Study: risk factors for the progression of open-angle glaucoma. Arch Ophthalmol 2008;126:1030-6
   PubMed Web of Science ®Google Scholar
• Zimmerman TJ, Hahn SR, Gelb L, et al. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther 2009;25:145-52
   PubMed Web of Science ®Google Scholar
• Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol 2008;53(Suppl 1):S107-S120
   PubMedGoogle Scholar
• Liang Y, Woodward DF, Guzman VM, et al. Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes. Br J Pharmacol 2008;154:1079-93
   PubMed Web of Science ®Google Scholar
• Katz LJ, Cohen JS, Batoosingh AL, et al. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol 2010;149:661-71
   PubMed Web of Science ®Google Scholar
• International Dry Eye Workshop. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:163-78
   PubMed Web of Science ®Google Scholar
• Hamacher T, Airaksinen J, Saarela V, et al. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol Suppl (Oxf) 2008;242:14-19
   PubMedGoogle Scholar
• Hommer A, Mohammed RO, Burchert M, et al. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma. Curr Med Res Opin 2010;26:1905-13
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Pillunat LE, Ropo A. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol 2010;88:12-19
   PubMed Web of Science ®Google Scholar
• Liang H, Brignole-Baudouin F, Pauly A, et al. Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study. Adv Ther 2011;28:311-25
   PubMed Web of Science ®Google Scholar
• Brignole-Baudouin F, Riancho L, Liang H, et al. In vitro comparative toxicology of polyquad-preserved and benzalkonium chloride-preserved travoprost/timolol fixed combination and latanoprost/timolol fixed combination. J Ocul Pharmacol Ther 2011;27:273-80
   PubMed Web of Science ®Google Scholar
• Denis P, Gandolfi S, Stalmans I, et al. Travoprost BAK-free formulation preserved with polyquaternium-1 is an effective option for achieving IOP reduction while eliminating BAK exposure in glaucoma patients. Presented at: European Glaucoma Society (EGS) congress 2010
   Google Scholar
• van der Valk V, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005;112:1177-85
   PubMed Web of Science ®Google Scholar
• Holmstrom S, Buchholz P, Walt J, et al. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr Med Res Opin 2005;21:1875-83
   PubMed Web of Science ®Google Scholar
• Denis P, Lafuma A, Khoshnood B, et al. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Curr Med Res Opin 2007;23:601-8
   PubMed Web of Science ®Google Scholar
• van der Valk V, Webers CA, Lumley T, et al. A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. J Clin Epidemiol 2009;62:1279-83
   PubMed Web of Science ®Google Scholar
• Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma 2008;17:667-73
   PubMed Web of Science ®Google Scholar
• Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003;135:55-63
   PubMed Web of Science ®Google Scholar
• Cantor LB, Hoop J, Morgan L, et al. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol 2006;90:1370-3
   PubMed Web of Science ®Google Scholar
• Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol 2004;137:S3-12
   PubMed Web of Science ®Google Scholar
• Dasgupta S, Oates V, Bookhart BK, et al. Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care 2002;8:S255-S261
   PubMed Web of Science ®Google Scholar
• Diestelhorst M, Schaefer CP, Beusterien KM, et al. Persistency and clinical outcomes associated with latanoprost and beta-blocker monotherapy: evidence from a European retrospective cohort study. Eur J Ophthalmol 2003;13(Suppl 4):S21-S29
   Google Scholar
• Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol 2008;53(Suppl 1):S57-S68
   PubMed Web of Science ®Google Scholar
• Watson PG, Barnett MF, Parker V, et al. A 7 year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma. Br J Ophthalmol 2001;85:962-8
   PubMed Web of Science ®Google Scholar
• World Glaucoma Association. Medical Treatment of Glaucoma (WGA Consensus Series 7). Amsterdam: Kugler Publications, 2010
   Google Scholar
• Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging 2007;24:1007-16
   PubMed Web of Science ®Google Scholar
• Chrai SS, Makoid MC, Eriksen SP, et al. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci 1974;63:333-8
   PubMed Web of Science ®Google Scholar
• Royal Pharmaceutical Society. NICE clinical guideline 85. Glaucoma – quick reference sheet for pharmacists. Available at: http://www.rpsgb.org.uk/pdfs/glaucomaguid.pdf [Last accessed 24 June 2010]
   Google Scholar
• Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol 2010;4:1-9
   PubMedGoogle Scholar
• Dunker S, Schmucker A, Maier H. Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol. Adv Ther 2007;24:376-86
   PubMed Web of Science ®Google Scholar
• Schwartz GF, Patel VD, Burk C, et al. Patient persistency with topical glaucoma therapy is higher with fixed dose brimonidine/timolol than with two-bottle combinations. Presented at: Association for Research in Vision and Ophthalmology 2010
   Google Scholar
• Higginbotham EJ, Hansen J, Davis EJ, et al. Glaucoma medication persistence with a fixed combination versus multiple bottles. Curr Med Res Opin 2009;25:2543-7
   PubMed Web of Science ®Google Scholar
• De Natale R, Draghi E, Dorigo MT. How prostaglandins have changed the medical approach to glaucoma and its costs: an observational study of 2228 patients treated with glaucoma medications. Acta Ophthalmol Scand 2004;82:393-6
   PubMedGoogle Scholar
• Vorwerk C, Thelen U, Buchholz P, et al. Treatment of glaucoma patients with insufficient intraocular pressure control: a survey of German ophthalmologists in private practice. Curr Med Res Opin 2008;24:1295-301
   PubMed Web of Science ®Google Scholar
• Kenigsberg PA. Changes in medical and surgical treatments of glaucoma between 1997 and 2003 in France. Eur J Ophthalmol 2007;17:521-7
   PubMed Web of Science ®Google Scholar
• Barnebey HS, Orengo-Nania S, Flowers BE, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol 2005;140:1-7
   PubMed Web of Science ®Google Scholar
• Konstas AG, Boboridis K, Tzetzi D, et al. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol 2005;123:898-902
   PubMed Web of Science ®Google Scholar
• Lazaridou MN, Montgomery DM, Ho WO, et al. Changes in intraocular pressure following a switch from latanoprost monotherapy to latanoprost/timolol fixed combination therapy in patients with primary open-angle glaucoma or ocular hypertension: results from a clinical practice database. Curr Med Res Opin 2008;24:2725-8
   PubMed Web of Science ®Google Scholar
• Hommer A. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol 2007;17:53-62
   PubMed Web of Science ®Google Scholar
• Brandt JD, Cantor LB, Katz LJ, et al. Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma 2008;17:211-16
   PubMed Web of Science ®Google Scholar
• Centofanti M, Oddone F, Vetrugno M, et al. Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study. Eur J Ophthalmol 2009;19:66-71
   PubMed Web of Science ®Google Scholar
• Martinez A, Sanchez M. A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma. Curr Med Res Opin 2007;23:1025-32
   PubMed Web of Science ®Google Scholar
• Martinez A, Sanchez M. Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients. Eye 2009;23:810-18
   PubMed Web of Science ®Google Scholar
• Centofanti M, Oddone F, Gandolfi S, et al. Comparison of travoprost and bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination. Am J Ophthalmol 2010;150:575-80
   PubMed Web of Science ®Google Scholar
• Topouzis F, Melamed S, Danesh-Meyer HV, et al. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol 2007;17:183-90
   PubMed Web of Science ®Google Scholar
• Rossi GC, Pasinetti GM, Bracchino M, et al. Switching from concomitant latanoprost 0.005% and timolol 0.5% to a fixed combination of travoprost 0.004%/timolol 0.5% in patients with primary open-angle glaucoma and ocular hypertension: a 6-month, multicenter, cohort study. Expert Opin Pharmacother 2009;10:1705-11
   PubMed Web of Science ®Google Scholar
• Denis P, Lafuma A, Jeanbat V, et al. Intraocular pressure control with latanoprost/timolol and travoprost/timolol fixed combinations: a retrospective, multicentre, cross-sectional study. Clin Drug Investig 2008;28:767-76
   PubMed Web of Science ®Google Scholar
• Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials. Eur J Ophthalmol 2011;Epub ahead of print
   Google Scholar
• Stewart WC, Kruft B, Nelson LA, et al. Ophthalmologist attitudes regarding fixed combination treatment for glaucoma in the European Union. Eur J Ophthalmol 2009;19:588-93
   PubMed Web of Science ®Google Scholar